Advanced Enzyme Technologies Limited share price
NSE: ADVENZYMES · ISIN INE837H01020
Key numbers
- Market cap
- ₹ 3,212 Cr
- Current price
- ₹ 291.15
- 52-week high / low
- ₹ 419 / 252
- Stock P/E
- 19.7
- Book value
- ₹ 145.8
- Dividend yield
- 0.88%
- ROCE
- 15.1%
- ROE
- 11.1%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- 11.3%
- Profit growth (3 yrs)
- 16.9%
- 1-year return
- -13.0%
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain, fungal proteases, and bacterial alpha amylase. It also provides probiotics for human and animal nutrition. In addition, the company offers enzymes and probiotics for fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, oils and fats processing, biofuels, and specialty applications. Further, it provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 186 | 185 | 172 | 203 | 190 |
| Operating profit | 56 | 60 | 49 | 63 | 51 |
| Net profit | 40 | 43 | 43 | 43 | 37 |
| EPS (₹) | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 |
Concall summary (2026-08-18)
AI summary of the earnings call transcript · tone: Neutral · source document
Guidance & outlook
- Consequently, the EBITDA margin stood at 27% compared to 30% in Q1 FY26 and 31% in Q4 FY26.
- The PAT margin for the quarter was 20% compared to 22% in both Q1 FY26 and Q4 FY26.
Growth & demand
- Our top line for the quarter stood at INR 1,898 million, registering a 2% YoY growth.
- Turning to Bioprocessing, the segment reported revenues of INR 306 million, delivering 30% YoY growth.
Margins & costs
- EBITDA for the quarter came in at INR 510 million, down 10% YoY and 19% QoQ.
- JC Biotech revenue stood at INR 195 million, and EBITDA of INR 26 million, PAT of INR 10 million as compared to revenue of INR 211 million, EBITDA of INR 33 million and PAT of INR 14 million in the Q1 of FY26.
Capex & expansion
- The company has also announced the acquisition of the remaining stake of 4.28% for a consideration of INR 79.79 million in our existing subsidiary, JC Biotech, resulting in a total stake of 100%, making it wholly-owned subsidiary.
- Just correct me if I'm wrong, but I think in the AGM minutes , the CapEx number, which was highlighted, was somewhere close to a INR 120-130 odd crores.
Balance sheet & cash
- We are pleased to announce that the Board has approved a buyback of INR 697 million at a ceiling price of INR 500 per share via open market route.
- Our debt is about 20% of our revenue as compared to 22% in Q1 FY26.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.